No CrossRef data available.
Article contents
La Commission Romanow et les médicaments: pour l'accessibilité à une pharmacothérapie de qualité
Published online by Cambridge University Press: 31 March 2010
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Editorials: Perspectives on the Romanow Commission Report/Éditoriaux : Perspectives sur le Rapport de la Commission Romanow
- Information
- Canadian Journal on Aging / La Revue canadienne du vieillissement , Volume 22 , Issue 1 , Spring/Printemps 2003 , pp. 29 - 32
- Copyright
- Copyright © Canadian Association on Gerontology 2003
References
Références
1Commission sur l'avenir des soins de santé au Canada. Guidé par nos valeurs: l'avenir des soins de santé au Canada—rapport final. Ottawa: Gouvernement du Canada; 2002.Google Scholar
2Taylor, MG. Health insurance and Canadian public policy: the seven decisions that created the Canadian health insurance system and their outcomes. 2e éd. Montréal: McGill-Queen's University Press; 1987.Google Scholar
3Millar, WJ. Disparités des régimes d'assurance-médicaments. Rapports sur la santé 1999;10:11–21.Google Scholar
4Institut canadien d'information sur la santé. Drug expenditure in Canada, 1985–2001. Ottawa: Institut canadien d'information sur la santé; 2002.Google Scholar
5Willison, D, Grootendorst, P, Hurley, J. Variation in pharmacare coverage across Canada. Document de travail 9808 du McMaster Centre for Health Economics and Policy Analysis Research; septembre 1998.Google Scholar
6Menec, VH, MacWilliam, L, Sooden, RA et Mitchell, L. (2002). The health and health care use of Manitoba's seniors: have they changed over time? Winnipeg, MB: Centre d'élaboration et d'évaluation de la politique des soins de santé au Manitoba.Google Scholar
7Soumerai, SB, Ross-Degnan, D, Avorn, J, McLaughlin, T, Choodnovskiy, I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991;325:1072–7.Google Scholar
8Tamblyn, R, Laprise, R, Hamley, JA, Abrahamowicz, M, Scott, S, Mayo, N, et al. . Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421–9.Google Scholar
9Cox, ER, Henderson, RR. Prescription use behaviour among medicare beneficiaries with capped prescription benefits. J Managed Care Pharmacy 2002;8:360–4.CrossRefGoogle ScholarPubMed
10Kozyrskyj, AL, Morgan, S, Dahl, M. Manitoba prescription cost data: an analysis for the Romanow Commission (données non publiées). Winnipeg, MB; September 2002.Google Scholar
11Willcox, SMM, Himmelstein, DU, Woolhandler, D. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994;272: 292–6.CrossRefGoogle ScholarPubMed
12Tamblyn, RM, McLeod, PJ, Abrahamowicz, M, Monette, J, Gayton, DC, Berkson, L, et al. . Questionable prescribing for elderly patients in Quebec. CMAJ 1994; 150: 1801–9.Google Scholar
13Mannesse, CK, Derkx, FHM, de Ridder, MAJ, Veld, AJM, van der Cammen, TJM. Contribution of adverse drug reactions to hospital admissions of older patients. Age Ageing 2000;29:35–9.Google Scholar
14Lipton, HL, Bero, LA, Bird, JA, McPhee, SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing: a randomized controlled trial. Med Care 1992;30:646–58.Google Scholar
15Anderson, GF, Hussey, PS. Population aging: a comparison among industrialized countries. Health Aff 2000 mai/juin;19:191–203.CrossRefGoogle ScholarPubMed
16Romanow, RJ. Déclaration sur la publication du rapport final de La Commission sur l'avenir des soins de santé au Canada, l'Amphithéâtre national de la presse, Ottawa, le 28 novembre, 2002. http://www.healthcare-commission.ca/ (March 5, 2003).Google Scholar
You have
Access